Our company is a R&D driven biotechnology firm specializing in therapeutic and diagnostic seeds for pancreatic cancer. We are developing antibodies that target pancreatic cancer stem cells and products utilizing unique antibodies derived from pancreatic cancer patients. Dedicated to bringing early diagnostic tools and effective treatments for pancreatic cancer to patients as quickly as possible, our goal is to ensure that our drug seeds and innovative technologies make a significant contribution to the treatment and early detection of pancreatic cancer.
We are conducting clinical development of an oral therapeutic cancer vaccine. We have completed a Phase I clinical trial targeting urothelial carcinoma and are currently conducting a Phase I/IIa clinical trial for malignant pleural mesothelioma.
Utilizing the unique genome editing technology CRISPR-Cas3, C4U develops industrial applications to combat diseases that currently have no effective treatments.
A startup developing kidney disease treatments and cell therapies using iPS cell technology, expanding its achievements in the kidney disease field while advancing applications to the liver and pancreas.
A startup leveraging its proprietary language processing technology, SATOMI®, to support the automatic generation of medical records and referral letters. By streamlining information use in clinical settings, it promotes regional collaboration and medical DX, contributing to the development of a sustainable healthcare system.